Genprex Inc. (NASDAQ:GNPX) Stock Continues To Trend Higher: What’s the Buzz?
If you are currently looking into gene therapy companies, then Genprex Inc. (NASDAQ:GNPX) could well be the one to follow after its stock ended up with gains of 38% yesterday amidst heavy trading. The move in the stock came about after a significant new announcement from the company on Monday.
Major Breakthrough
Yesterday the company came on to the radars of investors after it announced that the company’s research collaborators had delivered poster presentations at a key industry event. The event in question was the 024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics that had taken place from October 23 to October 25 in Barcelona, Spain.
Key Details
At the event, the research collaborators had presented posters with regards to the strong preclinical data from Reqorsa Gene Therapy, the lead drug candidate from Genprex. The product in question is meant for the treatment of those suffering from glioblastoma, mesothelioma, and lung cancer resistant to Ras inhibitors.
The data was presented to a highly influential audience populated primarily by those involved in oncology research. In fact, it was also noted that the company had already filed for two patents on the basis of the data that had been exhibited in the two posters. It could be a good time to add the Genprex stock to your watch lists for the week.
Management Comment
“We are pleased by this promising preclinical data, presented before a prestigious audience of oncology researchers, of REQORSA’s potential in serious and difficult-to-treat cancers, including KRAS G12C mutant lung cancer, mesothelioma, and glioblastoma,” said Ryan Confer, President and Chief Executive Officer at Genprex. “The role of TUSC2 in lung cancer has been well established, and TUSC2 restoration is being evaluated clinically. However, we are highly encouraged by our preclinical programs to expand the potential use of REQORSA to treat a variety of cancer indications, where patient populations have unmet medical needs.”
Traders Notes
| +/- EMA(20) | 1.42 (+71.83%) |
| +/- SMA(50) | 0.73 (+234.25%) |
| +/- SMA(200) | 2.65 (-7.92%) |
| 5-Day Perf. | -32.03% |
| 1-Month Perf. | +557.68% |
| 3-Month Perf. | +34.07% |
| 6-Month Perf. | +6.55% |
| YTD Perf. | -73.48% |
| 1-Year Perf. | -69.39% |
| RSI(14) | 64.21 |
| ATR(14) | 0.46 |
| ADX(14) | 54.19 |
| Beta (5Y) | 1.41 |